What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...

Unfortunately, medical treatments for Alzheimer’s disease and dementia have remained minimal for over 25 years, and with a ...

Discover breaking news detailing why the NHS will not cover two new Alzheimer’s drugs due to the high annual costs.

The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for ...

New immunotherapy drugs offer some hope in the fight against Alzheimer's disease but they're too pricey for the NHS ...

To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...

Donanemab is given monthly, via intravenous infusion. What does the evidence say? Australia’s approval of donanemab comes as a result of a clinical trial involving 1,736 people published in 2023.

Donanemab was licensed for use in the UK last year but is still only available privately as it was not deemed to be cost-effective enough to be subsidised by the National Health System (NHS).

Donanemab, recently approved by the FDA, offers new hope for patients in the early stages of Alzheimer’s disease—slowing memory loss by up to 29% over 18 months (1 Trusted Source ...

Nice concluded that donanemab slows the rate of decline in symptoms, but is not a cure. We don’t know enough about the long-term effects or the cost-effectiveness of this treatment. Nice consulted ...

Donanemab is approved to treat adults in the early stages of Alzheimer’s disease who have one or no copies of the apolipoprotein E4 gene (ApoE4). A person can have no copies, one copy or two of ...